Filing Flows › Enanta Pharmaceuticals (ENTA) › R&D spending
Enanta Pharmaceuticals (ENTA) R&D spending by quarter
Enanta Pharmaceuticals' R&D spending was $22.1M in Q3 FY26 (third quarter fiscal 2026), +14% from Q2 FY26. Over the last 7 quarters it ranged from $19.4M (Q2 FY26) to $30.8M (Q4 FY24).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 FY26 | $22.1M | +14% | -19% |
| Q2 FY26 | $19.4M | -7% | -31% |
| Q1 FY26 | $20.9M | -12% | — |
| Q4 FY25 | $23.8M | -12% | -23% |
| Q3 FY25 | $27.2M | -3% | — |
| Q2 FY25 | $28.1M | -9% | — |
| Q4 FY24 | $30.8M | — | — |
Q3 FY26 at a glance
Enanta Pharmaceuticals, Q3 FY26: revenue $14.4M (-22% year over year), operating margin -120.0%, net loss $19.5M, operating cash flow −$10.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Enanta Pharmaceuticals' R&D spending?
Enanta Pharmaceuticals' R&D spending was $22.1M in Q3 FY26 (third quarter fiscal 2026), +14% from Q2 FY26.
How has Enanta Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $19.4M (Q2 FY26) to $30.8M (Q4 FY24).
Q3 FY26 results → · How Enanta Pharmaceuticals makes money →